Drug Approval | February 20, 2022
Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Subscribe To Our Newsletter & Stay Updated
